 Thursday 6th June 2024 |
 5:30PM - 7:15PM Pacific Time |  RSM US LLP 3430 Carmel Mountain Rd Ste 200 San Diego, CA 92121 |
|---|
Monday 10th June 2024 |
5:30PM - 7:15PM Pacific Time | Global Victoria 575 Market St Ste 800 San Francisco, CA 94105 |
|---|
Dr. Rita Choueiri, National Director of Life Sciences at RSM Australia, is a leading figure in Research and Development (R&D) Incentives and Grants....
Leveraging her scientific background and nearly two decades of consulting experience, she guides STEM companies through the intricacies of R&D Tax Incentives, specialising in securing funding for growth and innovation. Rita’s unique blend of expertise, from drug development to financial strategies, positions her as a crucial bridge between science and finance, benefiting both clients and the industry.
Christine Lys, MS, ACRP-CP has been in the clinical research arena for over 30 years. Christine joined Catalyst in 2019 and has been actively engaged in cultivating research solutions for biotechnology companies with a focus in oncology....
Prior to Catalyst, Christine has worked across the industry from the investigative site, sponsor and CRO perspective and has contributed to initiatives to help create efficiencies in clinical research across therapeutic areas to ultimately transform patient lives. Christine is passionate about patients and making a difference in the methods in which we conduct clinical research. She spent nearly a decade in the clinical software technology arena, advocating increased quality and efficiency in clinical trials data collection. Previously she held executive positions with technology/medical device companies, where she served on executive and product development committees and procured pharmaceutical and medical device business opportunities. Prior to this, Christine was a Director of Business Development for a CRO at UnitedHealth Group. Christine began her career in clinical research at the Department of Psychiatry at Case Western Reserve University where she conducted psychiatric clinical research. She holds a Master’s degree in Biology and an undergraduate degree in Psychology from Case Western Reserve University.
Outside of work, Christine is the proud mother of two active young men and an international competitive Latin dancer with her beloved husband.
Dr. Alfred Botchway has over 25 years’ experience including academic, pharmaceutical and contract research organization tenure performing research studies designed to; investigate pharmacokinetic / pharmacodynamics profiles, minimize potential toxic and/or undesirable effects of agrochemical, biotechnological and pharmaceutical products on physiological functions prior to administration to the intended population....
Dr. Botchway was the founder of Xenometrics a non-clinical contract research organization that provided pharmacokinetic, toxicological and safety pharmacology services to the biopharmaceutical and agrochemical industry. Subsequent to 12 years of successfully operating Xenometrics, Alfred exited Xenometrics a year after its sale to a multinational contract research organization. Alfred is an active member of several international scholastic professional scientific organizations. Alfred served as the President of the International Safety Pharmacology Society and continues to be an active Past President. Most recently, Alfred served as the interim President and Board Chair of BioKansas, a state trade organization for bioscience companies. Dr. Botchway holds a Ph.D. in Cardiovascular Physiology from Imperial College of Science, Technology and Medicine, University of London, UK., and a Diplomate in Safety Pharmacology from the Society of Safety Pharmacology.
Meg has worked in the clinical trials industry for 25 years and is extremely passionate about bringing new innovation to patients....
Meg joined Catalyst Clinical Research in April 2023 as the Head of Development Operation for Asia Pacific. In this role Meg works to oversees operations of clinical trial in the Asia Pacific region. Prior to this Meg lead the clinical trials support unit at the Ingham Institute for Applied Medical Research and South Western Sydney Local Health District where she held the role of Executive Director of Clinical Trials. In this role Meg is responsible for supporting clinical trial activities in South Western Sydney leading to extensive patient access to over 700 clinical trials across 5 major hospitals.
Meg has a diverse background in clinical trials working in hospitals, general practice, pharmaceutical and biotech companies and contract research organisations. She has managed phase I-IV clinical trials across many therapeutic areas including medical oncology, haematology, cardiology, neurology, immunology and gastroenterology.
Before joining the Ingham Institute and South Western Sydney Local Health District Meg worked for IQVIA for 8 years in various senior management roles including Regulatory and Site Start Up, Project Management, Functional Service Provision, Medical Writing, Data Management & Biostatistics, Medical Services and Operations. Meg lead IQVIA Australia’s Biotech Delivery Unit which she helped establish to provide customers full service phase I-II clinical trials with services based in Australia for biotech companies to be able to claim the R&D tax incentive.
